Helft G, Vacheron A, Samama M M
Clinique cardiologique de l'hôpital Necker, Paris.
Arch Mal Coeur Vaiss. 1995 Jan;88(1):85-9.
The prothrombin time is the coagulation time of citrated plasma in the presence of calcium and a tissue extract, thromboplastin, added in excess. The prothrombin time was historically the first method of evaluation and control of oral anticoagulation. Over the years, the different thromboplastins have changed, diversified, so affecting the result of the prothrombin ration established from the prothrombin time and a reference curve. In 1985, the International Committee on Thrombosis and Haemostasis requested that all the losts of thromboplastin have their international sensitivity index (ISI) indicated. This allowed uniformity of the results by the introduction of the INR (International Normalized Ratio) calculated by the formula: INR = (PTR)ISI, the PTR or prothrombin time ratio corresponding to the patients' prothrombin time divided by that of reference control plasma. It is, in fact, impossible to interpret the results of a prothrombin ration without knowing their expression in INR. The consequences of the absence of uniformity in the control of anticoagulant therapy are important and serious. The uncertainty concerning the degree of anticoagulation inherent in the use of a single prothrombin ratio may be the source of bleeding or thromboembolic complications. Curiously, the system based on the INR is neither generalised, nearly 10 years after its recommendation, nor adopted by the majority of practitioners. However, the stakes are high because the principal complication of oral anticoagulants remains bleeding, including the dramatic strokes. Moreover, the global mortality due to haemorrhagic complications is about 0.1 to 0.5% for treatments of short duration and much higher in prolonged therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
凝血酶原时间是指在加入过量的钙和组织提取物(凝血活酶)的情况下,枸橼酸盐血浆的凝固时间。凝血酶原时间在历史上是评估和控制口服抗凝治疗的第一种方法。多年来,不同的凝血活酶发生了变化、多样化,从而影响了根据凝血酶原时间和参考曲线建立的凝血酶原比值的结果。1985年,国际血栓形成与止血委员会要求所有凝血活酶制剂都标明其国际敏感指数(ISI)。这通过引入按公式计算的国际标准化比值(INR)实现了结果的一致性:INR = (PTR)ISI,其中PTR或凝血酶原时间比值是患者的凝血酶原时间除以参考对照血浆的凝血酶原时间。事实上,如果不知道凝血酶原比值在INR中的表达,就无法解释其结果。抗凝治疗控制缺乏一致性的后果是重大且严重的。使用单一凝血酶原比值时抗凝程度的不确定性可能是出血或血栓栓塞并发症的根源。奇怪的是,基于INR的系统在其被推荐近10年后既未得到广泛应用,也未被大多数从业者采用。然而,风险很高,因为口服抗凝剂的主要并发症仍然是出血,包括严重的中风。此外,短期治疗因出血并发症导致的全球死亡率约为0.1%至0.5%,长期治疗时则更高。(摘要截断于250字)